A phase 1 study for a stem cell derived agent that promotes the growth of new nerve cells in the brain demonstrated efficacy in a very small sample of patients diagnosed with major depression (MDD). The phase 1B study was published online December 8 in Molecular Psychiatry.
MIA relies on the support of its readers to exist. Please consider a donation to help us provide news, essays, podcasts and continuing education courses that explore alternatives to the current paradigm of psychiatric care. Your tax-deductible donation will help build a community devoted to creating such change.